urologytimes4d
Darolutamide is safe, efficacious in mHSPC regardless of patient age
"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...
urologytimes3d
Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC
The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.
urologytimes3d
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...
urologytimes3d
Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC
Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...
urologytimes6d
Fred Saad, MD, shares phase 3 ARANOTE findings by disease volume
“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS In this video, Fred Saad, MD, FRCS, shares key findings ...
urologytimes6d
STOPCAP: ARPIs benefit younger patients with mHSPC
ARPIs provide significant survival benefits in younger mHSPC patients, with a 13% improvement in 5-year overall survival and 21% in progression-free survival. The meta-analysis included data from 11 ...
urologytimes6d
TALAPRO-2: Talazoparib/enzalutamide confers significant OS benefit in mCRPC
Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...
urologytimes6d
Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC
Darolutamide demonstrated longer treatment duration and delayed progression to metastatic CRPC compared to enzalutamide and apalutamide in Black and White patients. The DEAR and DEAR-EXT studies ...
urologytimes7d
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares future ...
urologytimes7d
BOND-003 Trial and Cretostimogene for Treatment of NMIBC
Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune ...
urologytimes4d
Gopa Iyer, MD, on durbable efficacy of EV/pembrolizumab in urothelial carcinoma
"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...